Corvus Pharmaceuticals Inc
NASDAQ:CRVS
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company is headquartered in Burlingame, California and currently employs 28 full-time employees. The company went IPO on 2016-03-23. The firm develops drugs and antibodies that target the critical cellular elements of the immune system. The firm's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company is headquartered in Burlingame, California and currently employs 28 full-time employees. The company went IPO on 2016-03-23. The firm develops drugs and antibodies that target the critical cellular elements of the immune system. The firm's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.
Financials: Corvus reported a third quarter net loss of $10.2 million, a significant improvement from the prior year’s $40.2 million loss.
Cash Position: The company ended Q3 with $65.7 million in cash, cash equivalents, and marketable securities, projecting this will fund operations into Q4 2026.
R&D Focus: Increased R&D expenses in the quarter were driven by advancing soquelitinib clinical trials, especially for atopic dermatitis and T-cell lymphomas.
Clinical Milestones: Phase I extension Cohort 4 for atopic dermatitis is fully enrolled, with data expected in January; Phase II atopic dermatitis trial to start in early Q1 2026.
Oncology Progress: The Phase III trial in peripheral T-cell lymphoma (PTCL) is enrolling, targeting interim data by late 2026.
Strategic Outlook: Corvus sees broad opportunity for soquelitinib in additional immune and inflammatory diseases, with plans for more trials and possible future partnerships or fundraising.
